399

In the review risk factors which transformations chronic atrophic a gastritis in a stomach cancer promote are analyzed. The characteristic of precancer conditions as increase in risk of development of a cancer of a stomach is given. Processes of a chronic inflammation, an atrophy, intestinal metaplasia, displasia and risk of formation adenocarcinoma of stomach are estimated. As risk factor of a cancer of a stomach definition of subtypes intestinal metaplasia is offered, dividing on full and incomplete taking into account decrease in an expression gastric mucin MUC1, MUC5AC and MUC6. The role of a genetic susceptibility of an organism to infected Н pylori, the factors of its pathogenicity promoting metaplasia epithelium is analyzed. It is proved that the combination virulence a microorganism and a genetic susceptibility of the owner conducts to heavier chronic inflammation and faster progressing of a cancer of a stomach, at least, for intestinal type the role of genetic polymorphism interleukins in pathogenesis gastric carcinogenesis is revealed. The association of risk of development of a cancer of a stomach with genotypes interleukins 1 (IL-1B-511 T, IL-1B-31 T, and a genotype *2/*2 the antagonist of a receptor interleukins 1 with the relation of chances 2,5 is established; 2,6 and 3,7 for development of a cancer of a stomach at homozygous These carriers alleles in comparison with not carriers. Also role Toll-like of receptors 4 types (TLR4), participating in recognition Н. pylori is established. Development of the superfluous immune answer of the owner is connected with receptors of this type, leading to damage of a mucous membrane at Н. pylori-infected persons. In particular, carriers TLR4+896А>G polymorphism have heavier atrophy of a stomach and inflammation degree, and also the raised risk a stomach cancer

  • Ссылка в интернете
  • DOI10.26739/2181-9300-2018-4-4
  • Дата создание в систему UzSCI25-11-2019
  • Количество прочтений0
  • Дата публикации19-12-2018
  • Язык статьиIngliz
  • Страницы
English

In the review risk factors which transformations chronic atrophic a gastritis in a stomach cancer promote are analyzed. The characteristic of precancer conditions as increase in risk of development of a cancer of a stomach is given. Processes of a chronic inflammation, an atrophy, intestinal metaplasia, displasia and risk of formation adenocarcinoma of stomach are estimated. As risk factor of a cancer of a stomach definition of subtypes intestinal metaplasia is offered, dividing on full and incomplete taking into account decrease in an expression gastric mucin MUC1, MUC5AC and MUC6. The role of a genetic susceptibility of an organism to infected Н pylori, the factors of its pathogenicity promoting metaplasia epithelium is analyzed. It is proved that the combination virulence a microorganism and a genetic susceptibility of the owner conducts to heavier chronic inflammation and faster progressing of a cancer of a stomach, at least, for intestinal type the role of genetic polymorphism interleukins in pathogenesis gastric carcinogenesis is revealed. The association of risk of development of a cancer of a stomach with genotypes interleukins 1 (IL-1B-511 T, IL-1B-31 T, and a genotype *2/*2 the antagonist of a receptor interleukins 1 with the relation of chances 2,5 is established; 2,6 and 3,7 for development of a cancer of a stomach at homozygous These carriers alleles in comparison with not carriers. Also role Toll-like of receptors 4 types (TLR4), participating in recognition Н. pylori is established. Development of the superfluous immune answer of the owner is connected with receptors of this type, leading to damage of a mucous membrane at Н. pylori-infected persons. In particular, carriers TLR4+896А>G polymorphism have heavier atrophy of a stomach and inflammation degree, and also the raised risk a stomach cancer

Русский

Проанализированы факторы риска, способствующие трансформации хронического атрофического гастрита в рак желудка. Дана характеристика предраковых состояний в порядке увеличения риска развития рака желудка. Оценены процессы хронического воспаления, атрофии, кишечной метаплазии, дисплазии и риск формирования аденокарциномы желудка. В качестве фактора риска рака желудка предложено определение подтипов кишечной метаплазии, разделяя на полную и неполную с учетом снижения экспрессии желудочных муцинов MUC1, MUC5AC и MUC6. Проанализирована роль генетической восприимчивости организма к инфицированности Н. pylori, факторы его патогенности, способствующие метаплазии эпителия. Доказано, что сочетание вирулентности микроорганизма и генетической восприимчивости хозяина ведет к более тяжелому хроническому воспалению и более быстрому прогрессированию рака желудка, по крайней мере, для кишечного типа. Выявлена роль генетического полиморфизма интерлейкинов в патогенезе желудочного канцерогенеза. Установлена ассоциация риска развития рака желудка с генотипами интерлейкина 1 (IL-1B-511 T, IL-1B-31 T, и генотипом *2/*2 антагониста рецептора интерлейкина 1 с отношением шансов 2,5; 2,6 и 3,7 для развития рака желудка у гомозиготных носителей этих аллелей по сравнению с не носителям. Также установлена роль Toll-like рецепторов 4 типа (TLR4), участвующих в распознавании Н. pylori. Именно с рецепторами этого типа связано развитие избыточного иммунного ответа хозяина, приводящее к повреждению слизистой оболочки у Н. pyloriинфицированных лиц. В частности, носители TLR4+896А>G полиморфизма имеют более тяжелую атрофию желудка и степень воспаления, а также повышенный риск некардиального рака желудка.

Имя автора Должность Наименование организации
1 Sobirova G. .
2 ABDULLAEVA .K.
Название ссылки
1 1.Prohorov, A. V., Labunec, I., Kazakevich, O., & Shepet’ko, M. (2014). Rak jeludka u pacientov moloje 30 let [Stomach cancer in patients younger than 30 years]. Evrazijskij onkologicheskij jurnal, (2), 64-68.
2 2.Chissov, V. I., Starinskij, V. V., & Petrova, G. V. (2013). Kachestvennye novoobrazovaniya v Rossii v 2011 godu (zabolevaemost’ i smertnost’) [malignant neoplasms in Russia in 2011 (morbidity and mortality)]. M.: FP «MNIOI im. PA Gercena» Minzdrava Rossii.
3 3.Amieva, M. R., & El–Omar, E. M. (2008). Host-bacterial interactions in Helicobacter pylori infection. Gastroenterology, 134(1), 306-323.
4 4.Bernini, M., Barbi, S., Roviello, F., Scarpa, A., Moore, P., Pedrazzani, C., ... & de Manzoni, G. (2006). Family history of gastric cancer: a correlation between epidemiologic findings and clinical data. Gastric Cancer, 9(1), 9-13.
5 5. Buffart, T. E., Carvalho, B., Hopmans, E., Brehm, V., Kranenbarg, E. K., Schaaij‐Visser, T. B., ... & Meijer, G. A. (2007). Gastric cancers in young and elderly patients show different genomic profiles. The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland, 211(1), 45-51.
6 6. Correa, P. (2004). The biological model of gastric carcinogenesis. IARC scientific publications, (157), 301-310.
7 7. Dinis-Ribeiro, M., Yamaki, G., Miki, K., Costa-Pereira, A., Matsukawa, M., & Kurihara, M. (2004). Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. Journal of Medical Screening, 11(3), 141-147.
8 8. Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., Rosso, S., Coebergh, J. W. W., Comber, H., ... & Bray, F. (2013). Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. European journal of cancer, 49(6), 1374-1403.
9 9. Fuccio, L., Zagari, R. M., Minardi, M. E., & Bazzoli, F. (2007). Systematic review: Helicobacter pylori eradication for the prevention of gastric cancer.Alimentary pharmacology & therapeutics, 25(2), 133-141.
10 10. Fuccio, L., Zagari, R. M., Eusebi, L. H., Laterza, L., Cennamo, V., Ceroni, L., ... & Bazzoli, F. (2009). Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer?. Annals of internal medicine, 151(2), 121-128.
11 11. Guindi, M., & Riddell, R. H. (2001). The pathology of epithelial pre-malignancy of the gastrointestinal tract. Best Practice & Research Clinical Gastroenterology, 15(2), 191-210.
12 12. Gutierrez-Gonzalez, L., & Wright, N. A. (2008). Biology of intestinal metaplasia in 2008: more than a simple phenotypic alteration. Digestive and liver disease, 40(7), 510-522.
13 13. Maruta, F., Sugiyama, A., Ishizone, S., Miyagawa, S., Ota, H., & Katsuyama, T. (2005). Eradication of Helicobacter pylori decreases mucosal alterations linked to gastric carcinogenesis in Mongolian gerbils. Journal of gastroenterology, 40(1), 104-105
14 14. Mera, R., Fontham, E. T., Bravo, L. E., Bravo, J. C., Piazuelo, M. B., Camargo, M. C., & Correa, P. (2005). Long term follow up of patients treated for Helicobacter pylori infection. Gut, 54(11), 1536-1540.
15 15. Nozaki, K., Shimizu, N., Ikehara, Y., Inoue, M., Tsukamoto, T., Inada, K. I., ... & Tatematsu, M. (2003). Effect of early eradication on Helicobacter pylori‐related gastric carcinogenesis in Mongolian gerbils. Cancer science, 94(3), 235-239
16 16. Ohata, H., Kitauchi, S., Yoshimura, N., Mugitani, K., Iwane, M., Nakamura, H., ... & Shimizu, Y. (2004). Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. International journal of cancer, 109(1), 138-143.
17 17. Pharoah, P. D., Guilford, P., Caldas, C., & International Gastric Cancer Linkage Consortium. (2001). Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology, 121(6), 1348-1353.
18 18. Pimanov, S. I., Makarenko, E. V., Voropaeva, A. V., Matveenko, M. E., & Voropaev, E. V. (2008). Helicobacter pylori eradication improves gastric histology and decreases serum gastrin, pepsinogen I and pepsinogen II levels in patients with duodenal ulcer. Journal of gastroenterology and hepatology, 23(11), 1666-1671.
В ожидании